{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:05:00Z","timestamp":1762430700030},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.cld.2012.11.005","type":"journal-article","created":{"date-parts":[[2012,12,21]],"date-time":"2012-12-21T02:24:11Z","timestamp":1356056651000},"page":"331-344","source":"Crossref","is-referenced-by-count":7,"title":["Care of the Cholestatic Patient"],"prefix":"10.1016","volume":"17","author":[{"given":"Andrea A.","family":"Gossard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.cld.2012.11.005_bib1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2007.05.008","article-title":"Diagnosis and management of cholestatic liver disease","volume":"5","author":"Heathcote","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4 Pt 1","key":"10.1016\/j.cld.2012.11.005_bib2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/hep.1840120423","article-title":"Review of hepatic imaging and a problem-oriented approach to liver masses","volume":"12","author":"Bennett","year":"1990","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2012.11.005_bib3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1089-3261(03)00077-1","article-title":"Liver imaging. A hepatologist's perspective","volume":"6","author":"Reddy","year":"2002","journal-title":"Clin Liver Dis"},{"issue":"26","key":"10.1016\/j.cld.2012.11.005_bib4","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJM199706263362607","article-title":"Imaging of the hepatobiliary tract","volume":"336","author":"Saini","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.cld.2012.11.005_bib5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.7326\/0003-4819-139-7-200310070-00006","article-title":"Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease","volume":"139","author":"Romagnuolo","year":"2003","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.cld.2012.11.005_bib6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0009-9260(99)90023-5","article-title":"The diagnostic accuracy of magnetic resonance cholangiopancreatography and ultrasound compared with direct cholangiography in the detection of choledocholithiasis","volume":"54","author":"Varghese","year":"1999","journal-title":"Clin Radiol"},{"issue":"13","key":"10.1016\/j.cld.2012.11.005_bib7","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJM199609263351301","article-title":"Complications of endoscopic biliary sphincterotomy","volume":"335","author":"Freeman","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 6","key":"10.1016\/j.cld.2012.11.005_bib8","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/S0016-5107(02)70010-2","article-title":"Evidence-based assessment of diagnostic modalities for common bile duct stones","volume":"56","author":"Mark","year":"2002","journal-title":"Gastrointest Endosc"},{"issue":"6","key":"10.1016\/j.cld.2012.11.005_bib9","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/S0016-5085(03)00390-1","article-title":"Biliary imaging: a review","volume":"124","author":"Baillie","year":"2003","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2012.11.005_bib10","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1572-0241.2002.05699.x","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system","volume":"97","author":"Heathcote","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2012.11.005_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.21229","article-title":"Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis","volume":"44","author":"Poupon","year":"2006","journal-title":"Hepatology"},{"issue":"21","key":"10.1016\/j.cld.2012.11.005_bib12","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.3748\/wjg.14.3368","article-title":"Overlap syndromes among autoimmune liver diseases","volume":"14","author":"Rust","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.cld.2012.11.005_bib13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.7326\/0003-4819-125-7-199610010-00009","article-title":"The variant forms of autoimmune hepatitis","volume":"125","author":"Czaja","year":"1996","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.cld.2012.11.005_bib14","first-page":"287","article-title":"Benign recurrent intrahepatic cholestasis: a long-term follow-up","volume":"41","author":"Nakamuta","year":"1994","journal-title":"Hepatogastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2012.11.005_bib15","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1053\/jhep.2002.37136","article-title":"Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome","volume":"36","author":"Colombo","year":"2002","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2012.11.005_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4065\/73.3.285","article-title":"Idiopathic adulthood ductopenia: an update","volume":"73","author":"Ludwig","year":"1998","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.cld.2012.11.005_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MOG.0b013e3282f9e239","article-title":"An update on primary sclerosing cholangitis","volume":"24","author":"Maggs","year":"2008","journal-title":"Curr Opin Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2012.11.005_bib18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1055\/s-2007-979469","article-title":"Interpreting serological tests in diagnosing autoimmune liver diseases","volume":"27","author":"Invernizzi","year":"2007","journal-title":"Semin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2012.11.005_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gut.2004.046615","article-title":"PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis","volume":"54","author":"Loftus","year":"2005","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cld.2012.11.005_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1148\/radiology.149.1.6412283","article-title":"Primary sclerosing cholangitis: findings on cholangiography and pancreatography","volume":"149","author":"MacCarty","year":"1983","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.cld.2012.11.005_bib21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/j.gastro.2008.01.042","article-title":"The natural history of small-duct primary sclerosing cholangitis","volume":"134","author":"Bjornsson","year":"2008","journal-title":"Gastroenterology"},{"issue":"9204","key":"10.1016\/j.cld.2012.11.005_bib22","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)72401-6","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"355","author":"Lindor","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cld.2012.11.005_bib23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2012.11.005_bib24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.1840160315","article-title":"Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial","volume":"16","author":"Beuers","year":"1992","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2012.11.005_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/07853899409148349","article-title":"Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis","volume":"26","author":"Stiehl","year":"1994","journal-title":"Ann Med"},{"issue":"10","key":"10.1016\/j.cld.2012.11.005_bib26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis. Mayo primary sclerosing cholangitis-ursodeoxycholic acid study group","volume":"336","author":"Lindor","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2012.11.005_bib27","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2007.12.023","article-title":"High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective","volume":"48","author":"Cullen","year":"2008","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2012.11.005_bib28","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2012.11.005_bib29","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2012.11.005_bib30","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1365-2036.2011.04863.x","article-title":"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis","volume":"34","author":"Imam","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cld.2012.11.005_bib31","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1572-0241.2001.03690.x","article-title":"Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis","volume":"96","author":"Kaya","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.cld.2012.11.005_bib32","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/j.1440-1746.2012.07109.x","article-title":"Pathogenesis and management of pruritus in cholestatic liver disease","volume":"27","author":"Imam","year":"2012","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2012.11.005_bib33","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0016-5085(88)90442-8","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial","volume":"94","author":"Ghent","year":"1988","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2012.11.005_bib34","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/ncpgasthep0746","article-title":"Is rifampin a safe and effective treatment for pruritus caused by chronic cholestasis?","volume":"4","author":"Heathcote","year":"2007","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2012.11.005_bib35","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/0016-5085(92)90335-V","article-title":"Effects of long-term rifampicin administration in primary biliary cirrhosis","volume":"102","author":"Bachs","year":"1992","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2012.11.005_bib36","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/BF01300759","article-title":"Treatment of pruritus of primary biliary cirrhosis with rifampin","volume":"36","author":"Podesta","year":"1991","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.cld.2012.11.005_bib37","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/gut.50.3.436","article-title":"Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis","volume":"50","author":"Prince","year":"2002","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.cld.2012.11.005_bib38","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/hep.510230551","article-title":"The pruritus of cholestasis is relieved by an opiate antagonist: is this pruritus a centrally mediated phenomenon?","volume":"23","author":"Heathcote","year":"1996","journal-title":"Hepatology"},{"issue":"3 Pt 1","key":"10.1016\/j.cld.2012.11.005_bib39","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0190-9622(99)70117-9","article-title":"Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study","volume":"41","author":"Bergasa","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6662","key":"10.1016\/j.cld.2012.11.005_bib40","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1136\/bmj.297.6662.1501","article-title":"Opioid peptides and primary biliary cirrhosis","volume":"297","author":"Thornton","year":"1988","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.cld.2012.11.005_bib41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-123-3-199508010-00001","article-title":"Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial","volume":"123","author":"Bergasa","year":"1995","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.cld.2012.11.005_bib42","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/0016-5085(95)90709-2","article-title":"The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids","volume":"108","author":"Bergasa","year":"1995","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2012.11.005_bib43","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","article-title":"Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study","volume":"113","author":"Wolfhagen","year":"1997","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2012.11.005_bib44","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first-line treatment for cholestatic pruritus","volume":"45","author":"Mayo","year":"2007","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2012.11.005_bib45","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/00042737-199810000-00010","article-title":"Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial","volume":"10","author":"Muller","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2012.11.005_bib46","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1365-2036.2005.02430.x","article-title":"A\u00a0controlled trial of ondansetron in the pruritus of cholestasis","volume":"21","author":"O'Donohue","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2012.11.005_bib47","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1093\/clinids\/13.Supplement_1.S94","article-title":"Definition and measurement of fatigue","volume":"13","author":"Barofsky","year":"1991","journal-title":"Rev Infect Dis"},{"issue":"1","key":"10.1016\/j.cld.2012.11.005_bib48","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.1840120116","article-title":"The demography of primary biliary cirrhosis in Ontario, Canada","volume":"12","author":"Witt-Sullivan","year":"1990","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2012.11.005_bib49","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/gut.43.5.705","article-title":"Fatigue in primary biliary cirrhosis","volume":"43","author":"Cauch-Dudek","year":"1998","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cld.2012.11.005_bib50","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1572-0241.2000.01857.x","article-title":"Impact of fatigue on the quality of life of patients with primary biliary cirrhosis","volume":"95","author":"Huet","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2012.11.005_bib51","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/0016-5085(95)90696-7","article-title":"A\u00a0placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid","volume":"108","author":"Vuoristo","year":"1995","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2012.11.005_bib52","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2012.11.005_bib53","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2012.11.005_bib54","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/hep.510290229","article-title":"Quality of life before and after liver transplantation for cholestatic liver disease","volume":"29","author":"Gross","year":"1999","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2012.11.005_bib55","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00042737-200012030-00017","article-title":"Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: report of two cases","volume":"12","author":"Katsinelos","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2012.11.005_bib56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1155\/2006\/624832","article-title":"Fatigue in liver disease: pathophysiology and clinical management","volume":"20","author":"Swain","year":"2006","journal-title":"Can J Gastroenterol"},{"issue":"11","key":"10.1016\/j.cld.2012.11.005_bib57","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s10620-006-9397-5","article-title":"Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial","volume":"51","author":"Talwalkar","year":"2006","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.cld.2012.11.005_bib58","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrgastro.2010.62","article-title":"Fatigue in primary biliary cirrhosis","volume":"7","author":"Abbas","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2012.11.005_bib59","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1007\/s10620-008-0613-3","article-title":"Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience","volume":"54","author":"Ian Gan","year":"2009","journal-title":"Dig Dis Sci"},{"issue":"Suppl 4","key":"10.1016\/j.cld.2012.11.005_bib60","first-page":"1211A","article-title":"Modafinil in the treatment of fatigue in patients with primary biliary cirrhosis","volume":"54","author":"Silveira","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2012.11.005_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/CS19990372","article-title":"Fatigue in chronic disease","volume":"99","author":"Swain","year":"2000","journal-title":"Clin Sci (Lond)"},{"issue":"4","key":"10.1016\/j.cld.2012.11.005_bib62","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1053\/bega.2000.0109","article-title":"Pruritus and fatigue in primary biliary cirrhosis","volume":"14","author":"Bergasa","year":"2000","journal-title":"Baillieres Best Pract Res Clin Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2012.11.005_bib63","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/lt.20104","article-title":"Bone mineral density among cirrhotic patients awaiting liver transplantation","volume":"10","author":"Sokhi","year":"2004","journal-title":"Liver Transpl"},{"issue":"4 Pt 1","key":"10.1016\/j.cld.2012.11.005_bib64","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/jhep.2002.36357","article-title":"Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry","volume":"36","author":"Guichelaar","year":"2002","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2012.11.005_bib65","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1136\/gut.49.2.282","article-title":"Osteoporosis in primary biliary cirrhosis revisited","volume":"49","author":"Newton","year":"2001","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cld.2012.11.005_bib66","first-page":"47","article-title":"Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment","volume":"89","author":"Crippin","year":"1994","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2012.11.005_bib67","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2036.2004.01890.x","article-title":"Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial","volume":"19","author":"Pereira","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.cld.2012.11.005_bib68","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s10620-006-8015-x","article-title":"Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen\/progestin","volume":"51","author":"Boone","year":"2006","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10.1016\/j.cld.2012.11.005_bib69","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.cld.2012.11.005_bib70","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1478-3231.2005.01026.x","article-title":"Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study","volume":"25","author":"Levy","year":"2005","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.cld.2012.11.005_bib71","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1572-0241.2003.07639.x","article-title":"Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis","volume":"98","author":"Guanabens","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.cld.2012.11.005_bib72","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/00365520510023279","article-title":"Effects of alendronate on bone mass in patients with primary biliary cirrhosis and osteoporosis: preliminary results after one year","volume":"40","author":"Musialik","year":"2005","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2012.11.005_bib73","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.20866","article-title":"Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial","volume":"42","author":"Zein","year":"2005","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2012.11.005_bib74","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1111\/j.1572-0241.2001.04134.x","article-title":"Fat-soluble vitamin levels in patients with primary biliary cirrhosis","volume":"96","author":"Phillips","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2012.11.005_bib75","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/0016-5085(85)90642-0","article-title":"Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification","volume":"89","author":"Jahn","year":"1985","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2012.11.005_bib76","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.dld.2011.07.020","article-title":"Serum lipids in primary sclerosing cholangitis","volume":"44","author":"Sinakos","year":"2012","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.cld.2012.11.005_bib77","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/0016-5085(89)90526-X","article-title":"Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival","volume":"96","author":"Gores","year":"1989","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2012.11.005_bib78","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/hep.510260508","article-title":"Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes","volume":"26","author":"Jones","year":"1997","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2012.11.005_bib79","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/hep.21907","article-title":"Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis","volume":"46","author":"Garcia-Tsao","year":"2007","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2012.11.005_bib80","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/gut.2004.040832","article-title":"Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection?","volume":"54","author":"Bressler","year":"2005","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.cld.2012.11.005_bib81","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2012.11.005_bib82","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cgh.2007.02.031","article-title":"Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis","volume":"5","author":"Levy","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2012.11.005_bib83","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cgh.2006.09.031","article-title":"Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis","volume":"5","author":"Suzuki","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2012.11.005_bib84","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cgh.2011.09.013","article-title":"Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma","volume":"10","author":"Imam","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2012.11.005_bib85","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1055\/s-2006-933562","article-title":"Primary sclerosing cholangitis and cholangiocarcinoma","volume":"26","author":"Lazaridis","year":"2006","journal-title":"Semin Liver Dis"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326112001444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326112001444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T11:33:04Z","timestamp":1562499184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326112001444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1089326112001444"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2012.11.005","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}